XOMA is a biopharmaceutical company that combines a portfolio of innovative therapeutic antibodies, both in preclinical research and late-stage clinical development, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a broad range of diseases.
The company announced that it has entered into an agreement with its partner, Les Laboratories Servier, and Boehringer Ingelheim to transfer XOMA’s technology and process for the commercial manufacture of gevokizumab, its novel interleukin 1-beta allosteric modulating antibody. Gevokizumab is currently in Phase 3 clinical development in patients with non-infectious uveitis, an inflammatory disease of the uvea, involving the intermediate and/or posterior segment of the eye. Financial terms of the deal between all the parties were not disclosed.
Upon completion of the transfer and the establishment of biological comparability, Boehringer is expected to produce givokizumab at its facility in Biberach, Germany, for XOMA’s commercial use. XOMA and Servier will retain all rights to the development and commercialization of givokizumab. The German company has more than 35 years of expertise in the area of manufacturing monoclonal antibodies on a commercial scale.
Other products in XOMA’s pipeline include the XMet Program, which is comprised of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could be important in the future treatment of diabetes. For additional information about XOMA and all its products, please visit the company’s website at www.xoma.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
